# SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease

> **NCT06155604** · PHASE2 · RECRUITING · sponsor: **The University of Hong Kong** · enrollment: 150 (estimated)

## Conditions studied

- Lupus Nephritis
- Chronic Kidney Diseases

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab
- **DRUG:** Standard maintenance therapy

## Key facts

- **NCT ID:** NCT06155604
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-04
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06155604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06155604, "SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06155604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*